Cagrilintide

What is Cagrilintide?

Cagrilintide is a synthetic long-acting analog of the naturally occurring hormone amylin. Amylin is co-secreted with insulin by pancreatic beta cells and plays a critical role in regulating appetite and glucose metabolism. Cagrilintide is specifically designed to target the amylin receptor, promoting satiety and reducing food intake.

Currently under clinical investigation, Cagrilintide has shown promise in the treatment of obesity and metabolic disorders when used alone or in combination with other weight-loss agents such as GLP-1 receptor agonists like semaglutide. Its extended half-life allows for once-weekly dosing, making it a convenient option for research into long-term weight management strategies.

Research Applications

Cagrilintide is being studied for its potential roles in:

• Appetite suppression and enhanced satiety for significant weight loss
• Improved glycemic control in individuals with obesity or type 2 diabetes
• Combination therapy for enhanced weight loss when paired with GLP-1 receptor agonists
• Reduction of cardiometabolic risk factors associated with obesity